Sign in
TerminatedNo phase

A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).

Key facts

Who runs it
Novo Nordisk A/S
Where
Germany1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
100 people enrolled
Started
8 Aug 2025
Ended
18 Dec 2025
Type of study
Observational, 2 groups
Treatments tested
  • Semaglutide
Record updated
27 April 2026
Why it stopped
The study was cancelled prematurely due to lack of patients.

Who can take part

Age
18 years and older
Sex
Women and men

The registry criteria, word for word

Show all 16 criteriaShow less

Other criteria

  • Common inclusion criteria for Group A and Group B:
  • Male or female, age above or equal to 18 years at the time signing informed consent
  • Body mass index (BMI) more than or equal to (≥) 30 kilogram per meter square (kg/m\^2) with at least one of the following diagnosed obesity-related comorbidities:; arterial hypertension, pre-diabetes, Obstructive Sleep Apnea (OSA) or coronary heart disease, chronic heart failure, or BMI ≥35 kg/m\^2
  • History of at least one self-reported unsuccessful attempt to lose weight
  • Capable of completing informed consent; Additional inclusion criteria for Group A:
  • The decision to initiate treatment with commercially available Wegovy has been made by the participant and the treating physician before and independently from the decision to include the participant in this study
  • Initiation of treatment is not modified in any case due to participant's participation in the study; Common exclusion criteria for Group A and Group B:
  • Previous participation in this study (participation is defined as having given informed consent in this study)
  • Treatment with an investigational drug within 30 days prior to enrolment into the study
  • Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy
  • Women with pregnancy or breast-feeding
  • Women of childbearing potential and not using an adequate contraceptive method
  • Men and women in their pregnancy attempts
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • History of any Glucagon-like peptide-1 (GLP-1) treatment within 180 days
  • History of type 1 or type 2 diabetes mellitus

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Participants will be treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician for the management of obesity. The purpose of this study is to collect data on the effect of Semaglutide under everyday conditions in participants. Participants and doctor had already decided that they will get semaglutide prescribed by doctor, independently of patient's participation in this study. The study will last for 12 months.

The 2 groups in the trial

  • Group A

    Participants will be treated with commercially available semaglutide along with lifestyle modification in the routine clinical practice.

    Treatment: Semaglutide

  • Group B

    Participants with lifestyle modification in the routine clinical practice will be included.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany Non-interventional.
Record updated
27 April 2026
A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany). (NCT07081178) – Frontlight Research